Home > Footprints > Asia Pacific

North America

North America

Humanwell is determined to provide global customers with top quality and affordable products by leveraging our superior manufacturing base in central China.

Humanwell’s North America expansion started in 2008, with the establishment of PuraCap Pharmaceutical in New Jersey. PuraCap specializes in research and development, manufacturing, and commercialization of soft gel prescription generic and OTC products. With its headquarters, R&D team, sales and marketing team in New Jersey, its state-of-the-art cGMP manufacturing facility (annual soft gel capacity of up to 6 billion) in Wuhan, and total employees of 300+, PuraCap supplies major US wholesalers and pharmacy chains with more than 200 products carrying major and store brands.

Humanwell acquired Epic Pharma, LLC in 2016. Epic is a leader in R&D, manufacturing and commercialization of oral solid dose and controlled substance prescription generics drugs in the US. Located in New York with employees of 230, Epic manufactures high quality prescription generics on behalf of its pharmaceutical clients such as Sandoz, and supplies to major wholesalers and group purchase organizations (GPOs) prescription generics under its own label. In addition to a total of 40 marketed products, the company owns a pipeline of 20 ANDAs, 12 filed to the FDA with pending approvals, and 10 in late stage development.

Humanwell, together with AGIC Capital, acquired the Ritedose Corporation in 2017.Ritedose is No. 1 in blow-fill-seal (BFS) unit-dose-sterile pharmaceutical manufacturing in the US, with annual capacity reaching 1.8 billion at its state-of-art, South Carolina-based facility. It manufactures branded and generic drugs on behalf of major pharmaceutical clients such as Teva, Mylan, Sandoz, and Shire, and sells generics under its own label to major wholesalers, group purchasing organizations (GPOs) and hospitals. Together with its pharmaceutical clients, Ritedose is responsible for about half of all nebulized respiratory drugs, and significant amount of branded ophthalmic drugs prescribed in the US.